Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting - Press Release

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of

Related Keywords

Georgia ,United States ,Sweden ,Atlanta ,American ,Swedish ,Krish Patel ,Allen Yang ,Xencor Xmab ,Exchange Commission ,American Society Of Hematology ,Janssen Biotech Inc ,Xencor Inc ,Lymphoma Program At Swedish Cancer Institute ,Janssen Pharmaceutical Companies Of Johnson ,Nasdaq ,Lymphoma Program ,Swedish Cancer Institute ,American Society ,Annual Meeting ,Janssen Biotech ,Janssen Pharmaceutical Companies ,Xmabb Cell ,Private Securities Litigation Reform Act ,